Akermin Completes $5 Million Financing Round

ST. LOUIS — Akermin, an innovative biocatalyst technologies company and the exclusive developer of proprietary stabilized enzyme catalyst technology, announces a successful funding round. The company raised $4,955,000 from venture capitalists and other private investors in its Series A Phase II financing round, the first stage of which was completed in March and the second in September 2007. All investors, including Prolog Ventures, OnPoint Technologies, Chrysalix Energy and the St. Louis Arch Angels, were previous Series A investors in Akermin. This latest round brings total funding since inception of the company to just under $8.5 million. Link.